Get 'More Cowbell' With This Oil Play
BMO Capital Markets upgraded Oasis Petroleum Inc. (NYSE: OAS) to Outperform from Market Perform, noting that the company's 2016 "game plan," which emphasizes abundant liquidity, is on track.
Analyst Dan McSpirit said that Oasis supported the firm's view that oil stocks should have a "defensive quality, with growth attached." McSpirit said that the sector's other Outperform stocks, including Carrizo Oil & Gas, Inc. (NASDAQ: CRZO), Matador Resources Co (NYSE: MTDR) and Synergy Resources Corp (NYSE: SYRG), also have that same spirit.
Related Link: Oil, Retail And More: This Week's ETFs To Watch
BMO said it was impressed that Oasis has wells "waiting on completion" which would "immediately contribute to production growth" if oil prices moved higher. Simultaneously, if oil prices remain lower, Oasis is "better positioned than most small-caps to weather" the climate.
Adding Oasis to a portfolio adds "torque, but in a way that the investor doesn't need to venture far out on the risk curve to get it." The company's leverage looks "elevated," but "liquidity remains abundant." Higher commodity prices will help the firm lower leverage, but regardless of where they move, McSpirit did not see the need for the firm to sell assets or equity.
Oasis was lower by nearly 3 percent on Monday, falling to $10.18. Year-to-date, the stock has sunk 38.5 percent, while prices are down 78 percent the past 12 months. BMO's $16 price target reflects a 57 percent upside to current prices. The stock last traded there in June.
Latest Ratings for OAS
Aug 2015 | BMO Capital | Upgrades | Market Perform | Outperform |
Aug 2015 | Wunderlich | Upgrades | Hold | Buy |
Jul 2015 | Cowen & Company | Initiates Coverage on | Outperform |
View More Analyst Ratings for OAS
View the Latest Analyst Ratings
See more from Benzinga
Doug Kass Doesn't Like Morgan Stanley's Massive Tesla Target Hike
RBC: Neos Therapeutics Has 70% Upside, 0 Million Opportunity
PacCrest: Apple's iPhone Growth Could Shrink, But It Won't Hurt Investors
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.